SE has achieved rapid commercial success with VYVGART, driving $4.2 billion in 2025 sales and operational profitability. Learn more about ARGX stock here.
This year’s Rare Disease Day event Feb. 27 at the Jacobs School of Medicine and Biomedical Sciences focused on updates in research and diagnostics, and advancements in treatment.
Learn how LEMS affects more than just muscles and explore tips for managing hidden symptoms like dry mouth, GI issues, and blurred vision while advocating for comprehensive care.
Argenx Se ( (ARGX)) has provided an update. On March 6, 2026, Argenx announced it will present extensive new data on VYVGART and its neurology pipeline at the American Academy of Neurology Annual ...
A decade ago, Doug Upton was the picture of strength as a U.S. Marine Corps officer stationed in Jordan. But in 2016, subtle warning signs emerged, indicating something wasn’t quite right. “My legs ...
AOM Infusion ("AOM"), a leading specialty infusion pharmacy and provider, today announced it has joined Kedrion Biopharma's limited distribution network for QIVIGY®, a new 10% immune globulin (Ig) ...
The Medicare Payment Advisory Commission is calling on Congress to rein in spending after it found tens of billions of dollars in overpayments. The insurance industry is pushing back on those findings ...
Odds are good you’ve encountered an identity theft protection service in the last year, even if you weren’t looking to sign ...
Wegovy is a Food and Drug Administration-approved weight loss medication for people with obesity or those who are overweight with weight-related health conditions. In recent years, interest in ...
Last summer, the Trump administration announced a voluntary pledge by health insurers to reform prior authorization, but patient advocates and medical providers remain skeptical.
For two years, she had battled the company to cover blood plasma infusions called intravenous immunoglobulin, or IVIG. The ...
More revenue from taxes, new collection methods, and a debt shifting changed Prince George's County's fortune.